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Aims/hypothesis—Few studies have explored the epidemiology of beta cell loss in youth with 
diabetes. This report describes the evolution and major determinants of beta cell function, assessed 
by fasting C-peptide (FCP), in the SEARCH for Diabetes in Youth study.
Methods—Participants were 1,277 youth with diabetes (948 positive for diabetes autoantibodies 
[DAs] and 329 negative for DAs), diagnosed when aged <20 years, who were followed from a 
median of 8 months post diagnosis, for approximately 30 months. We modelled the relationship 
between rate of change in log FCP and determinants of interest using repeated measures general 
linear models.
Results—Among DA-positive youth, there was a progressive decline in beta cell function of 4% 
per month, independent of demographics (age, sex, race/ethnicity), genetic susceptibility to 
autoimmunity (HLA risk), HbA1c and BMI z score, or presence of insulin resistance. Among DA-
negative youth, there was marked heterogeneity in beta cell loss, reflecting an aetiologically mixed 
group. This group likely includes youths with undetected autoimmunity (whose decline is similar 
to that of DA-positive youth) and youth with non-autoimmune, insulin-resistant diabetes, with 
limited decline (~0.7% per month).
Conclusions/interpretation—SEARCH provides unique estimates of beta cell function 
decline in a large sample of youth with diabetes, indicating that autoimmunity is the major 
contributor. These data contribute to a better understanding of clinical evolution of beta cell 
function in youth with diabetes, provide strong support for the aetiological classification of 
diabetes type and may inform tertiary prevention efforts targeted at high-risk groups.
Keywords
Beta cell function; Decline; Determinants; Epidemiology; Type 1 diabetes; Type 2 diabetes; 
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Introduction
Diabetes mellitus is a spectrum of metabolic diseases with distinct aetiologies, characterised 
by a progressive decline in beta cell function and mass [1, 2]. An increasing body of 
evidence demonstrates the importance of preserving endogenous beta cell function in 
patients with diabetes, regardless of aetiology or presumed diabetes type [3, 4]. However, 
there is a paucity of data regarding the epidemiology of beta cell function, including the rate 
and major determinants of beta cell decline, especially among contemporary youth with 
diabetes [5]. Limited information has been provided by interventional studies in youth with 
autoimmune diabetes [6–9] and individuals with adult-onset diabetes [10]. Recent data 
suggest that there is a progressive deterioration of beta cell function both before and after the 
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diagnosis of autoimmune diabetes [11, 12]; however, limited information is available 
regarding the factors that predict the rate of decline. Even less is known about the clinical 
evolution of beta cell function in youth without autoimmune diabetes. Moreover, most 
previous studies were designed to explore the effects of specific interventions, were usually 
much smaller and often included selected participants, making it difficult to draw 
conclusions applicable to the general population of youth with diabetes. Such data may be 
relevant for the aetiological classification of diabetes type.
SEARCH for Diabetes in Youth is a population-based, multicentre and multi-ethnic study of 
paediatric diabetes in the USA. With the aim of rigorously characterising the epidemiology 
of diabetes in youth, this study has carefully collected detailed clinical and 
pathophysiological data on a large number of youth with all types of diabetes. Moreover, 
SEARCH has recently developed operational definitions of diabetes types, as recommended 
by the ADA expert committee, using an aetiological approach based on assessment of 
autoimmunity and insulin resistance (IR), in which four aetiological subgroups were defined 
[13]. The purpose of this manuscript is to describe the presentation, short-term clinical 
evolution and major determinants of decline in beta cell function, as measured by fasting C-
peptide (FCP), in a general population of youth with diabetes, using data from the 
prospective cohort of the SEARCH for Diabetes in Youth study.
Methods
Overview
Data for these analyses derive from the SEARCH for Diabetes in Youth prospective cohort 
study. A detailed description of SEARCH study methods has been published elsewhere [14]. 
Briefly, SEARCH has been conducting population-based ascertainment of youth and young 
adults with newly diagnosed (incident) diabetes diagnosed when <20 years of age, starting 
in 2002 and continuing through to the present. SEARCH recruited participants from four 
geographically defined populations in the USA (Ohio, Colorado, South Carolina and 
Washington) and also Indian Health Service beneficiaries from several American Indian 
populations and enrollees in several managed healthcare plans in California and Hawaii. 
Participants with newly diagnosed diabetes in 2002–2005 were invited to participate in a 
baseline research visit (median duration of diabetes 8 months, interquartile range [IQR] 4.5–
14.5 months) and two follow-up exams centred around 12 and 24 months after their baseline 
visit. At each research visit fasting blood samples were obtained from metabolically stable 
participants (defined as no episode of diabetic ketoacidosis during the previous month), 
physical measurements were conducted and questionnaires were administered. The study 
was reviewed and approved by the local Institutional Review Board(s) that had jurisdiction 
over the local study population and all participants provided informed consent and/or assent.
Data collection
Study visits occurred after an 8 h overnight fast. Participants did not take diabetes 
medications on the morning of the visit and long-acting insulin was administered on the 
evening before the visit and then discontinued. Fasting blood samples were used to analyse 
diabetes autoantibodies (DAs), HbA1c, lipids and FCP and fasting plasma glucose (FPG). 
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Assays were performed at the Northwest Lipid Metabolism and Diabetes Research 
Laboratories, University of Washington, the Central Laboratory for SEARCH. Glutamic 
acid decarboxylase-65 (GADA) and insulinoma-associated-2 (IA-2A) autoantibodies were 
analysed using a standardised protocol and a common serum calibrator developed by the 
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored 
harmonisation group [15]. The cut-off values for positivity were 33 NIDDKU/ml for GADA 
and 5 NIDDKU/ml for IA-2A [15]. HbA1c was measured in whole blood with an automated 
nonporous ion-exchange HPLC system (model G-7; Tosoh Bioscience, San Francisco, CA, 
USA). Measurements of plasma cholesterol, triacylglycerols and HDL-cholesterol were 
performed on a Roche Modular-P autoanalyzer (Roche Diagnostics, Indianapolis, IN, USA). 
Levels of FCP were determined by a two-site immunoenzymetric assay (Tosoh 1800; Tosoh 
Bioscience) with a sensitivity of 0.05 ng/ml. Human leucocyte antigen class II genotyping 
(HLA DR/DQ) was performed with a PCR-based sequence-specific oligonucleotide probe 
system in the laboratories of S. Gaur (University of Washington, Seattle, WA, USA) and H. 
Erlich (Roche Molecular Systems, Pleasanton, CA, USA) on all consenting participants 
[16].
Weight and height were measured using standardised procedures and used to calculate BMI. 
Waist circumference was measured using the National Health and Nutrition Examination 
Survey (NHANES) III protocol [17].
Insulin sensitivity (IS) was estimated using the following equation: loge 
IS04.64725−0.02032 (waist, cm)−0.09779 (HbA1c, %)−0.00235 (triacylglycerol, mg/dl; to 
convert triacylglycerol values from mg/dl to mmol/l, multiply by 0.0113). This equation was 
developed and validated in a previous study [18] using direct measurements of glucose 
disposal rate from euglycaemic–hyperinsulinaemic clamps. IR was defined as an IS value 
below the 25th percentile in the general US youth population (<8.15), as previously 
described [13].
Data on self-reported race and ethnicity were collected using 2000 US Census questions [19] 
and classified as Hispanic, non-Hispanic white (NHW), non-Hispanic black, American 
Indian and Asian/Pacific islander.
Determinants of interest
Autoimmunity was defined by positive titres for either GADA or IA-2A at baseline. 
Because many participants were treated with insulin, positive insulin autoantibodies were 
not used. Genetic susceptibility to autoimmunity was defined based on HLA DR/DQ. HLA 
genotypes were categorised as susceptible (DR3/4, DR4/4, DR4/8, DR4/1, DR 4/13, DR 3/3, 
DR 3/9, DR 4/9 and DR 9/9 genotypes) and not susceptible, including neutral and protective 
genotypes [13], as recommended by the Type 1 Diabetes Genetic Consortium, with 
modifications for the multi-ethnic population [16]. For these analyses race/ethnicity was 
categorised as NHW and other than non-Hispanic white, including all other racial/ethnic 
groups. BMI z scores from measured height and weight at baseline visit were derived for age 
and sex using the US Centers for Disease Control and Prevention National Center for Health 
Statistics growth charts [20]. Finally, SEARCH participants were also classified according 
to baseline aetiological category of diabetes type in four mutually exclusive groups as 
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previously described [13]: autoimmune and insulin sensitive, autoimmune and insulin 
resistant, non-autoimmune and insulin sensitive, non-autoimmune and insulin resistant.
Study participants
The eligible study population consisted of all SEARCH participants who were diagnosed in 
2002–2005, who had a baseline visit with non-missing FCP, DA and demographic data, plus 
at least another follow-up visit with non-missing FCP. There were 2,763 individuals that had 
a baseline SEARCH visit and 1,895 participants had non-missing FCP, DA and 
demographic data at baseline. An additional sample of 629 were dropped because they did 
not have at least one follow-up visit with non-missing FCP, resulting in 1,277 SEARCH 
individuals contributing to this analysis. Of the 1,277 participants included in these analyses, 
634 contributed two visits (baseline plus one follow-up) and 643 contributed three visits 
(baseline plus two followup visits). There were 948 DA-positive participants (487 with 
double and 461 with single antibody positivity) and 329 DA-negative participants.
Statistical analyses
Statistical analyses were performed using SAS software (version 9.2; SAS Institute, Cary, 
NC, USA), with p<0.05 indicating significance. Comparisons of baseline participant 
characteristics by baseline DA status were examined using χ2 tests, t tests and Wilcoxon 
tests. Beta cell function was estimated using FCP concentration [21].
Using all baseline and follow-up data, we used mixed effects regression analysis to derive 
predicted FCP levels over time, based on fitted models that included up to three observed 
measures of FCP for each participant. These models adjust for the correlation between 
repeated observations in the same individual and have the advantage of handling a varying 
number of observations within individuals, thereby allowing for inclusion of the maximum 
number of data points [22]. Further, this method allows for a random intercept and slope in 
disease duration to account for within-individual dependence. These models incorporate 
duration of diabetes (actual time in months) as a continuous time-varying covariate and 
explore significant associations (statistical interactions) between determinants of interest 
(baseline DA status, age at diagnosis, sex, race/ethnicity, HLA DR/DQ susceptibility status, 
baseline BMI z score and HbA1c) and time (duration of diabetes) on FCP levels. All models 
are also adjusted for site- and time-varying FPG levels measured at each FCP measurement. 
Since baseline DA status emerged as the main determinant of FCP decline all analyses were 
stratified by baseline DA status. For DA-positive individuals, the effect of double vs single 
DA positivity at baseline on FCP decline over time was also explored, adjusting for all the 
covariates mentioned above. Age at diagnosis was modelled both continuously and 
categorically (<10 and ≥10 years, for illustrative purposes) with very similar results. To 
account for a skewed distribution of FCP levels, values were log-transformed for these 
analyses. Predicted FCP rate of change was expressed as per cent change in FCP level per 
month with 95% CIs.
Finally, we were also interested in modelling the rate of change in FCP levels as a function 
of baseline aetiological category of diabetes type. Therefore, a separate model was built to 
explore the association between the four-level aetiological diabetes type variable 
Dabelea et al. Page 5













(autoimmune and insulin sensitive, autoimmune and insulin resistant, non-autoimmune and 
insulin sensitive, non-autoimmune and insulin resistant) and log-transformed FCP over time. 
This analysis excluded 66 participants due to missing data on variables that are part of the IS 
equation.
Results
Baseline characteristics of study participants, stratified by baseline DA status, are shown in 
Table 1. As expected, DA-positive participants were younger at diagnosis, more likely to be 
of male sex and NHW race/ethnicity, more likely to have susceptible HLA DR-DQ 
genotypes and had lower FCP levels and BMI z scores, but higher baseline FPG levels, 
compared with those who were DA negative. Table 2 presents the number of individuals 
participating at each of the three SEARCH visits, their average diabetes duration at each 
visit and mean FCP and FPG levels, by DA status.
Table 3 presents the associations between baseline FCP levels and determinants of interest, 
from multivariable analyses stratified by baseline DA status. In both DA-positive and DA-
negative participants, younger age at diagnosis, NHW race/ethnicity, higher baseline HbA1c 
and lower baseline BMI z score were independently associated with significantly lower 
baseline FCP levels. In DA-positive participants only, male sex was also associated with 
lower baseline FCP levels. HLA DR/DQ susceptibility status was not significantly 
associated with FCP levels at baseline in either group.
Figure 1 shows predicted FCP levels over time among youth with positive DA at baseline, 
by age at diagnosis of diabetes (stratified as <10 and ≥10 years). The model showed that age 
at diagnosis, sex, race/ethnicity, HLA risk, baseline HbA1c and BMI z score were not 
associated with FCP decline over time (see electronic supplementary material [ESM] Table 
1). The predicted rate of decline in FCP levels among youth positive for DA (shown in Fig. 
1 for an average baseline HbA1c of 8%, BMI Z-score of 0.6 and an average time-varying 
FPG of 9.2 mmol/l) was 4.1% (95% CI 3.9, 4.3) per month, regardless of age at diagnosis, 
sex, race/ethnicity and HLA risk status. When baseline DA positivity status was added to the 
model, presence of two DAs vs one DA was the only variable significantly associated with 
faster decline in FCP levels (p<0.0001): estimated 4.4% (95% CI 4.1, 4.7) per month in 
those with double DA positivity vs 3.7% (95% CI 3.4, 4.0) per month in those with single 
DA positivity (ESM Table 2).
Figure 2 shows predicted FCP levels over time among youth with negative DA at baseline, 
by age at diagnosis of diabetes (<10 and ≥10 years). The model showed that age at 
diagnosis, race/ethnicity, HLA risk status, baseline HbA1c and BMI z score were 
independently associated with FCP decline over time (ESM Table 3). Predicted rates of 
decline are shown in Fig. 2 for an average baseline HbA1c of 7.5%, BMI z score of 1.3 and 
an average time-varying FPG of 7.3 mmol/l. The fastest rate of decline was predicted in 
youth of NHW race/ethnicity who had susceptible HLA DR/DQ genotypes (4.0% [95% CI 
3.1, 4.9] per month in youth diagnosed at <10 years of age and 3.2% [95% CI 2.4, 3.9] in 
those diagnosed at age ≥10 years). These estimates are very similar to those predicted for 
youth who were DA positive at baseline, suggesting undetected autoimmunity in this group 
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of SEARCH participants. Similarly, rates of decline that were consistently elevated were 
predicted among youth with susceptible HLA DR/DQ genotypes who were of other racial/
ethnic groups than NHW (2.9% [95% CI 1.9, 4.0] per month among those with age at 
diagnosis <10 years and 2.1% [95% CI 1.2, 2.9] per month among those with older age at 
diagnosis). These data also suggest an undetected autoimmune process, given the presence 
of susceptible HLA markers. The slowest rates of decline were predicted among DA-
negative youth of minority racial/ethnic groups who did not have susceptible HLA DR/DQ 
genotypes (1.4% [95% CI 0.6, 2.1] per month in those diagnosed at <10 years of age and 
0.5% [95% CI 0.1, and genetic markers of autoimmunity and also by a preponderance of 
minority racial/ethnic backgrounds. Interestingly, the group of NHW participants without 
susceptible HLA genotypes who were diagnosed at an age older than 10 years had an 
intermediate predicted rate of change, 2.5% (95% CI 1.7, 3.2) per month, likely marking an 
aetiologically mixed group of individuals with and without autoimmune diabetes.
Finally, predicted rates of decline in FCP levels by baseline aetiological category of diabetes 
type are presented in Table 4. Overall, baseline category of diabetes type was significantly 
associated with FCP decline (p<0.0001). The fastest rates of decline were predicted among 
youth with autoimmunity, regardless of whether they were insulin sensitive (4.0% [95% CI 
3.8, 4.3] per month) or insulin resistant (4.2% (95% CI 3.8, 4.7) per month). An intermediate 
rate of decline (2.4% [95% CI 1.9, 3.0] per month) was predicted for youth without evidence 
of autoimmunity who were insulin sensitive, while the predicted rate of decline among 
youth with non-autoimmune, insulin-resistant diabetes was significantly slower (0.7% [95% 
CI 0.3, 1.2] per month).
Discussion
Our study provides unique quantitative estimates of decline in beta cell function over the 
first 30 months following diagnosis of diabetes in a large, diverse sample of youth in the 
USA. SEARCH provides strong evidence that autoimmunity is the main driver of beta cell 
loss even after diabetes diagnosis. Among DA-positive youth, there is a progressive decline 
in beta cell function, independent of demographic factors, genetic susceptibility to 
autoimmunity (HLA risk), HbA1c levels and BMI z score. Among DA-negative youth, there 
is marked heterogeneity in beta cell loss, reflecting an aetiologically mixed group. Our data 
contribute to a better understanding of the clinical progression of diabetes in youth in the 
first years following diagnosis.
In youth with autoimmune diabetes there was an estimated decline in beta cell function of 
~4% per month, or approximately 40% per year. Similarly, in a series of 204 consecutive 
patients with type 1 diabetes, Snorgaard et al [23] reported that FCP levels (on average 0.5 
ng/ml at diagnosis) declined in a homogeneous manner at a rate of 0.24 ng/ml annually. 
Other studies have estimated the decline in beta cell function during the first year after 
diagnosis of type 1 diabetes, with variable results. Most of the recent studies are based on 
data provided by the control arm of intervention studies, include small numbers of highly 
selected participants and use stimulated C-peptide as the measure of beta cell function. 
While some report modest reduction in beta cell function at 1 year [24, 25], others report a 
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50% decline in the first year post-diagnosis [1, 26–28], consistent with our data in an 
unselected population.
There are limited data on factors influencing beta cell function in youth with autoimmune 
diabetes [12, 29–35]. We found that younger age, male sex, NHW race/ethnicity, higher 
HbA1c and lower BMI z score were each associated with lower FCP levels at baseline 
(Table 3). The Diabetes Prevention Trial-Type 1 (DPT-1) study has demonstrated that C-
peptide levels at diagnosis are much higher in individuals diagnosed through surveillance of 
those at high risk [36] compared with those diagnosed in the community, with signs and 
symptoms of hyperglycaemia. Our findings that higher HbA1c and lower BMI z score are 
associated with lower baseline FCP levels are consistent with DPT-1 findings, suggesting a 
more severe or longer preclinical course in those with less residual beta cell function at 
presentation. Consistent with our data, several reports have shown that younger age is 
associated with lower C-peptide levels at diagnosis with type 1 diabetes [8, 9, 36]. This may 
suggest a more aggressive preclinical course or an overall lower beta cell mass in younger 
children [6], while in older patients greater IR may lead to a clinical presentation at an 
earlier preclinical stage of disease [21, 37].
Although age, sex, race/ethnicity, HbA1c and BMI z score were each associated with lower 
FCP levels at baseline (Table 3), none of them were significantly associated with the 
subsequent rate of decline (Fig. 1). Based on our data, on average, residual beta cell function 
at any point in time is a function of baseline C-peptide levels and disease duration. Others 
have also reported that baseline C-peptide level is the strongest predictor of decline in beta 
cell function in youth [21] and young adults [38] with autoimmune diabetes.
One of our most novel findings is that markers of obesity and IR do not significantly 
influence the decline in FCP levels after diagnosis of autoimmune diabetes. Investigators 
and clinicians have previously described a group of youth with autoimmunity and obesity as 
having ‘hybrid’ or ‘double’ diabetes [39], suggesting a mixed aetiology and, likely, a more 
aggressive clinical evolution. The aetiological classification of diabetes type proposed by 
SEARCH [13] and findings from other recent studies [40] provide evidence that rather than 
being a distinct aetiological category this group represents the upper tail of the distribution 
of IR and obesity among youth with autoimmune diabetes. We now provide novel evidence 
that the rate of FCP decline in youth with autoimmune, insulin-resistant diabetes is not 
significantly different from that observed in youth with autoimmune, insulin-sensitive 
diabetes (4.2% [95% CI 3.8, 4.7] per month vs 4.0% [95% CI 3.8, 4.3] per month, p=0.5, 
Table 4). This was also suggested by baseline BMI z score not being significantly associated 
with decline in FCP levels in DA-positive youth. These findings lend additional support to 
the notion that type 1 diabetes is a distinct aetiological category and that the main driver of 
beta cell loss is autoimmunity, regardless of prevailing IR that may occur simultaneously. 
These findings also have important clinical implications indicating the importance of a 
correct diagnosis of autoimmune type 1 diabetes in obese youth, and thus adequate insulin 
treatment.
Less is known about the clinical history of beta cell function in youth with non-autoimmune 
diabetes. Although small studies suggested that youth with type 2 diabetes have some degree 
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of beta cell dysfunction at diagnosis [41, 42], there are no large prospective studies of the 
natural evolution and determinants of beta cell function in youth with type 2 diabetes. The 
estimated rate of decline among SEARCH youth who had non-autoimmune, insulin-resistant 
diabetes was 0.7% per month, or approximately 8% per year, in the first 30 months 
following diagnosis (Table 4). This is consistent with studies in adults showing a 7% decline 
annually [3, 43]. However, a recent study has suggested no signs of progressive beta cell 
damage during 20 years of prospective follow-up of autoantibody-negative, adult-onset 
diabetes [44], which contrasts with the generally held view of progressive beta cell loss in 
type 2 diabetes. There is an obvious need for long-term follow-up studies of individuals with 
youth-onset, non-autoimmune, type 2 diabetes.
Our study has some limitations and unique strengths. Because SEARCH is a large 
epidemiological study, we used fasting, rather than stimulated, C-peptide levels to assess 
baseline and change in beta cell function over time. FCP level is easy to obtain and 
correlates well with stimulated C-peptide [45–47], although it may be insufficient to detect 
subtle effects of therapy. In addition, we used a standard protocol to assess beta cell 
function, with all measurements conducted in the fasting state, in the absence of hypo-or 
hyperglycaemia, which are known to affect FCP levels [48]. Only a fraction of participants 
had FCP measures in the first 6 months after diagnosis and, therefore, during this period the 
rate of decline in FCP may have been estimated with less precision. Only two autoantibodies 
were measured in SEARCH. Thus, individuals who may have autoimmune markers other 
than GADA or IA-2A were misclassified as having non-autoimmune diabetes. However, the 
predicted rates of change in FCP levels based on models that included other characteristics, 
such as HLA DR/DQ susceptibility genotypes, race/ethnicity and age at diagnosis, identified 
groups of participants with likely undetected autoimmune diabetes. In addition, SEARCH is 
planning to assess ZnT8 autoantibodies in stored samples once assays are standardised. We 
also do not have follow-up data on all SEARCH participants. However, minimal differences 
existed between those who did (n=1,277) and did not participate (n=629) in the follow-up 
assessment. In particular, the proportion of DA-positive and DA-negative participants, the 
racial/ethnic distribution, the mean age and FCP levels according to DA status were not 
substantially different. Finally, our data are not the result of a randomised clinical trial, 
which is much better suited to address specific questions regarding the role of glycaemic 
control or that of specific therapies, on beta cell decline in youth with diabetes. Our study 
also has very important strengths. This is a unique cohort of youth with diabetes ascertained 
without regard to presumed diabetes type, family history or related factors, such as age, 
treatment or race/ethnicity, which has permitted us to accurately quantify progression of beta 
cell damage in a large sample of youth with diabetes.
In summary, SEARCH provides unique quantitative estimates of beta cell function decline 
over the first 30 months following diagnosis in a large sample of youth with diabetes in the 
USA. Our data provide strong evidence that autoimmunity is the main driver of beta cell 
loss even after diabetes diagnosis. We also provide novel evidence that markers of obesity 
and IR do not influence the decline in beta cell function in youth with autoimmune diabetes. 
Finally, youth with non-autoimmune, insulin-resistant diabetes have a much slower 
progression of beta cell dysfunction. These data contribute to a better understanding of 
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clinical evolution of beta cell function in youth with diabetes, provide strong support for the 
aetiological classification of diabetes type and may inform tertiary prevention efforts 
targeted at high-risk groups.
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Refer to Web version on PubMed Central for supplementary material.
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Estimated mean FCP levels and rate of monthly decline among youth with positive DA 
status at baseline; (a) age at diagnosis of diabetes <10; (b) age at diagnosis ≥10. Black 
symbols, HLA susceptible; grey symbols, HLA not susceptible; diamonds, NHW race/
ethnicity; triangles, other race. Multivariate mixed model predicting log-transformed FCP 
over time based on diabetes duration, age at diagnosis of diabetes, sex, race/ethnicity, HLA 
risk group, baseline HbA1c, BMI z score, site and time-varying fasting glucose (FPG). 
Estimates and rate of decline (95% CIs) are shown for an average baseline HbA1c of 8% 
(63.93 mmol/mol), BMI z score of 0.6 and an average time-dependent FPG of 9.2 mmol/l. 
The data under the graph present the number of FCP data points available in various time 
intervals
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Estimated mean FCP levels and rate of monthly decline among youth with negative DA 
status at baseline; (a) age at diagnosis of diabetes <10; (b) age at diagnosis ≥10. Black 
symbols, HLA susceptible; grey symbols, HLA not susceptible; diamonds, NHW race/
ethnicity; triangles, other race. Multivariate mixed model predicting log-transformed FCP 
over time based on diabetes duration, age at diagnosis of diabetes, sex, race/ethnicity, HLA 
risk group, baseline HbA1c, BMI z score, site and time-dependent fasting glucose (FPG) 
levels. Estimates and rates of decline (95% CIs) are shown for an average baseline HbA1c of 
7.5% (58.47 mmol/mol) and BMI z score of 1.3 and an average time-dependent FPG of 7.3 
mmol/l. The data under the graph present the number of FCP data points available in various 
time intervals
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Table 1
Characteristics of study participants, according to baseline DA statu
Characteristic DA positive DA negative p valuea
Number 948 329
Age at diagnosis (years) 9.6 (±3.9) 12.0 (±3.8) <0.0001
Age at diagnosis <10 years 436 (46.0) 73 (22.2) <0.0001
Sex
 Female 460 (48.5) 175 (53.2)   0.1
 Male 488 (51.5) 154 (46.8)
Race/ethnicity
 NHW 730 (77.0) 151 (45.9) <0.0001
 Hispanic 104 (11.0) 55 (16.7)
 Non-Hispanic black 83 (8.8) 77 (23.4)
 Asian/Pacific Islander 29 (3.1) 32 (9.7)
 American Indian 2 (0.2) 14 (4.3)
HLA DR-DQ group
 Susceptible 422 (47.1) 52 (17.5) <0.0001
 Not susceptible 474 (52.9) 245 (82.5)
FCP (nmol/l), median IQR) 0.17 (0.3) 0.62 (1.0) <0.0001
HbA1c (%) 7.6 (1.4) 7.3 (1.8)   0.0010
HbA1c (mmol/mol) 59.65 56.28
BMI z score 0.6 (1.0) 1.4 (1.2) <0.0001
FPG (mmol/l), mean (SD) 9.16 (4.09) 8.12 (3.89) <0.0001
Data are mean (±SD) or n (%) except where stated otherwise
a
p value from χ2 test (categorical) or t test (continuous) or Wilcoxon test (FCP only)
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Table 3
Determinants of baseline FCP levels from multivariate analyses, stratified by baseline DA status
Determinant DA positive DA negative
Effect, % (95% CI)a p value Effect, % (95% CI)a p value
Age at diagnosis (<10 vs ≥10 years) 44 (38, 49) <0.0001 57 (47, 65) <0.0001
Sex (male vs female) 11 (2, 19)   0.0185   0.1
Race (NHW vs others) 19 (9, 28)   0.0004 30 (15, 42)   0.0002
HLA (susceptible vs not susceptible)   0.7   0.5
Baseline HbA1c (per 1% increase) 19 (15, 22) <0.0001 7 (1, 13)   0.0170
Baseline BMI z score (per 1 unit decrease) 17 (13, 21) <0.0001 37 (32, 42) <0.0001
a
Percentage by which baseline FCP level is lower
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Table 4
Baseline FCP levels and estimated monthly decline in FCP, according to baseline aetiological category of 
diabetesa
Aetiological category n Baseline FCP (nmol/l), median (IQR) Estimated monthly decline, % (95% CI)
Autoimmune + insulin sensitive 688 0.17 (0.22) 4.0 (3.8, 4.3)
Autoimmune + insulin resistant 212 0.27 (0.42) 4.2 (3.8, 4.7)
Non-autoimmune + insulin sensitive 122 0.22 (0.33) 2.4 (1.9, 3.0)
Non-autoimmune + insulin resistant 189 1.13 (0.95) 0.7 (0.3, 1.2)
a
This analysis includes a slightly smaller number of SEARCH participants due to missing data on variables that are part of the IS equation Overall 
p<0.0001; adjusted for time-dependent FPG levels
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